Enavate Sciences and TPG, led a $157m Series B round in Sudo Biosciences, a biopharmaceutical company, with participation from Sanofi Ventures, Surveyor Capital, Monograph Capital, Eventide Asset Management, Frazier Life Sciences and Velosity Capital. “We are thankful for the support of our premier life science investors, which will allow us to advance our two development candidates into the clinic. With this financing, we are well positioned to progress our pipeline of next generation TYK2 inhibitors and pursue our mission of improving care for the millions of people living with multiple sclerosis, psoriasis and other severe autoimmune and neurologic conditions," Scott Byrd, Sudo Biosciences CEO.